Extended Data Table 1.

Summary of patient characteristics

Characteristics (n=60)	N (%)
Age (median/range)	71 (26–86)
Gender (male)	50 (83%)
Stage IIIC	2 (3%)
Stage IV
M1a	3 (5%)
M1b	20 (33%)
M1c	35 (58%)
Desmoplastic subtype
Pure	25 (42%)
Mixed	30 (50%)
Unknown	5 (8%)
BRAF V600 mutation (+)	1 (2%)
ECOG
0	29 (50%)
1	29 (50%)
2	1 (2%)
LDH
Elevated	12 (20%)
Normal	48 (80%)
Sites of metastases (may have multiple)
Brain	3 (5%)
Lung	34 (57%)
Liver	20 (33%)
Bone	13 (22%)
Prior lines of therapy for metastatic disease
0	18 (30%)
1	31 (52%)
2	11 (18%)
Prior ipilimumab therapy	30 (50%)
Response rate to prior ipilimumab therapy	2 (7%)